Cetero sold to investor group, renamed PRACS Institute

Wednesday, June 20, 2012 02:38 PM

Cary, N.C.-based Cetero Research has finalized the sale of the company to its investor group, led by Freeport Financial, following the company’s Chapter 11 bankruptcy filing court approval of the sale.

As part of the new ownership structure, the company’s headquarters will move to Fargo, N.D., and the company has been renamed PRACS Institute.

The board of directors has named three executive appointments to lead operational, financial and new business initiatives. James Carlson, Pharm.D, has been named CEO. Carlson has more than 30 years of experience in early phase research. He co-founded and served as CEO of Cetero Research, based in Fargo, N.D., from 1983 to 2006, where he oversaw the conduct of more than 450 studies per year across a range of therapeutic indications and study types.

Mark Ubert, CPA, MBA, has been named CFO. Ubert joined Cetero in 2009 as corporate controller. John Pottier has been named executive vice president, business development. Joining PRACS from Worldwide Clinical Trials, Pottier previously served in business development roles at Novum Research, Cetero Research and PRACS Institute, after beginning his career at the Clinical Research Foundation, now part of Quintiles Transnational.

Founded in 2004 by a group of corporate finance and capital markets professionals, Freeport Financial provides capital and leveraged finance solutions to middle market companies.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs